Another strong Announcement:
Mr Paul Rennie, CEO of Paradigm:
Repurposing PPS for hay fever represents a breakthrough in the treatment of hay fever i.e. one drug (PPS) which is steroid independent and has the potential to attenuate the symptoms of both the early and late phases of the disease. The global market for hay fever therapeutics is US$11bn. With a potential first-in-class drug for this massive market, the treatment of hay fever represents a major commercial opportunity for Paradigm.
Ann: Preclinical study underpins efficacy of Paradigm's RhinosulR-PAR.AX, page-2
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
0.135(41.5%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 49.5¢ | 34.0¢ | $3.506M | 8.474M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 45.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 147167 | 1 |
View Market Depth
| Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
